Group 1 - The core index of the Science and Technology Innovation Board (科创板) showed mixed performance, with the Science and Technology Growth Index rising by 0.2%, while the Science and Technology 50 Index and the Science and Technology Composite Index both fell by 0.3%, and the Science and Technology 100 Index decreased by 0.9% [1] - Guotai Junan Securities believes that the previous adjustments in the sector have been sufficient, and with stable annual report forecasts and continued high growth in the first quarter, if industrial catalysts emerge, the growth style is expected to return and potentially lead the overall market in the upcoming spring rally [1] Group 2 - Small and medium-sized technology companies in the electronic, pharmaceutical, power equipment, and computer industries account for over 80% of the sector, with a particularly high proportion in the electronic and pharmaceutical industries [4] - The Science and Technology Composite Index ETF by E Fund tracks the comprehensive index of the Science and Technology Innovation Board, covering all market securities and focusing on core frontier industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals, while providing high growth potential and risk diversification [4] - The Science and Technology Growth 50 ETF tracks the growth index of the Science and Technology Innovation Board, consisting of 50 stocks with high growth rates in operating income and net profit, highlighting the growth style and strong performance [4]

在多元投资策略中，具备独到的理念和稳健的业绩表现，才能成为业界瞩目的焦点。近日，北京止于至 善投资管理有限公司(以下简称"止于至善")总经理何理在接受《证券日报》记者专访时表示，回顾创业 至今的投资历程，坚持深耕全球私募投资逾十年，始终秉持只以"合理价格"和投资"卓越公司"的核心原 则，不断优化投资策略，构建科学严谨的投资体系，才能取得优异的产品业绩。 所谓"合理价格"和"卓越公司"，何理认为，卓越公司应同时具备竞争力强、成长性高、价值创造大的特 点；而合理价格则是在对上市公司进行理性估值后，有一定折扣时的价格。这一理念在全球市场均具有 可行性。 何理同时表示，本公司投研团队采用扁平化管理与交叉研究模式，所有数据共享，投研效率高。这种结 构适合持续运营全球价值投资策略，鼓励研究员"畅所欲言"和"劳有所得"。交叉研究和重复研究增加了 研究广度与深度，许多股票因研究员个人兴趣而产生"意外的惊喜"。 截至目前，止于至善实现了港、美、韩、日等多市场布局，美股敞口占比较高。不同市场的资产定价逻 辑与风险特征各异，但投资组合是自下而上构建的，不会刻意调整结构或整体择时。这种策略确保了组 合的稳定性和灵活性。 "从英伟达的 ...

中信建投（601066）证券认为，考虑到2026年产业景气预期，创新药有望成为跨年行情主要上涨方向。 中长期逻辑上，中国医药产业已迈入"创新兑现+全球布局"的关键阶段，人口与内需基数、全产业链制 造能力构成核心支撑，创新药长期产业趋势具备高度确定性。 自9月初至今，港股创新药板块回调幅度已超17%，前期高位风险得以充分释放。分析指出，当下或是 中长期维度配置创新药核心资产的较佳时机。 12月9日，港股通创新药板块加速走低，100%创新药研发标的——港股通创新药ETF（520880）跌幅扩 大逾2%，权重股普遍飘绿，康方生物、三生制药挫逾5%，信达生物跌近3%。"抄底"资金持续躁动，昨 日，超5600万元资金入场加仓港股通创新药ETF（520880），今日港股通创新药ETF（520880）持续溢 价，显示买盘资金强势。 把握港股创新药低吸窗口期，重点关注同类最大港股通创新药ETF（520880）及其场外联接基金 （025221），标的指数恒生港股通创新药精选指数具备三大独特优势：其一，纯粹，全面。不含 CXO，纯正创新药！全面覆盖创新药研发类公司；其二，龙头占比大。前十大创新药龙头权重超72%， 表征创新药硬核 ...

港股创新药概念走强，歌礼制药一度飙涨超20%，药明合联、药明生物、恒瑞医药等跟涨。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | | 01672 | 歌礼制药-B ● | 17.140 | +2.810 | 19.61% | | 02268 | 药明合联 | 69.700 | +2.350 | 3.49% | | 02269 | 药明生物 | 33.740 | +0.800 | 2.43% | | 01276 | 恒瑞医药 | 74.100 | +1.550 | 2.14% | | 00867 | 康哲药业 | 13.870 | +0.210 | 1.54% | | 01177 | 中国生物制药 | 6.850 | +0.070 | 1.03% | | 02096 | 先声药业 | 13.850 | +0.140 | 102% | 此番大涨背后，直接催化因素是歌礼制药昨晚公布的一项重磅临床研究结果。 研究显示，口服小分子 GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降达 7.7 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [36]. Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, along with the first version of the Commercial Health Insurance Innovative Drug List, was released on December 7, 2025. This adjustment includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [3]. - The newly launched Chinese Drug Price Registration System aims to facilitate the global pricing system for innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients [4][5]. - The innovative drug sector is expected to continue its rise, with recommendations to focus on companies with rich pipeline layouts, high-potential innovative drugs, and leading technology platforms [11]. Summary by Sections Industry Developments - The 2025 drug list adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and innovation in China [3]. - The Chinese Drug Price Registration System, launched on December 2, 2025, allows pharmaceutical companies to independently declare drug prices, promoting a more transparent and globalized pricing structure [4][5]. Company Highlights - Yino Pharmaceutical has rapidly emerged in the metabolic disease treatment field since its establishment in 2014, with its core product, Isupreglutide α, receiving approval as a Class 1 innovative drug and entering commercialization [7]. Investment Strategy - The report suggests focusing on companies with diverse pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group, as well as those with high-potential innovative drugs like Sanofi and Kaiyin Technology [11]. - It also highlights the importance of companies with leading technology platforms, such as Dongcheng Pharmaceutical and WuXi AppTec, as well as upstream companies benefiting from overseas expansion [11]. Market Performance - The pharmaceutical sector experienced a decline of 0.74% last week, ranking 19th among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.28% [14][24]. - As of December 5, 2025, the pharmaceutical sector's valuation stands at 29.30 times (TTM), with a premium of 17.46% over the overall A-share market [27].

Group 1 - The core viewpoint of the news highlights the significant increase in the success rate of national medical insurance negotiations, reaching a historical high, which is expected to encourage the development of innovative drugs in China [2] - The 2025 National Medical Insurance Drug List will add 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, marking a notable increase from 76% in 2024 [1] - The new drug list will officially implement on January 1, 2026, expanding the total number of drugs covered to 3,253, enhancing coverage in key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2 - Citic Securities believes that the successful negotiation rate for national medical insurance has reached a historical high, and the commercial insurance directory is expected to become an important growth driver, promoting the development of innovative drugs [2] - Guotai Junan Securities indicates that the recent press conference and series of discussions by the medical insurance bureau clarify future policies that support companies in "anti-involution," international expansion, and differentiated innovation, which will benefit the high-quality development of the medical device industry [2] - The China Innovation Drug ETF closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

Group 1 - The National Healthcare Security Administration released the first version of the "Medical Insurance + Commercial Insurance Dual Directory" on December 7, which may boost investment enthusiasm for innovative drugs in the short term [1] - The innovative drug sector has seen a recent stock price correction, but the long-term logic of the rise of Chinese innovative drugs remains unchanged, suggesting that investment opportunities in innovative drugs, CXO, and upstream life sciences should be emphasized [1] - High-end medical devices may present turning point opportunities, with pharmaceutical equipment benefiting from the overseas pharmaceutical investment upcycle and the recovery of in-hospital procurement driving business growth [1] Group 2 - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which had a daily fluctuation of 20%, reflecting the overall performance of listed companies engaged in innovative drug research and related businesses in China [1] - The index includes companies from the biopharmaceutical and chemical pharmaceutical sectors, highlighting the high R&D investment and technological innovation characteristics of the Chinese innovative drug industry [1]

板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | ...

近日，国家医疗保障局正式发布《国家基本医疗保险、工伤保险和生育保险药品目录（2025年）》。 值得关注的是，三生制药与上海海和药物研究开发股份有限公司合作的紫杉醇口服溶液成功纳入新版目录，成为本次 医保谈判中罕见的口服细胞毒类创新药之一。该目录将于2026年1月1日正式实施，标志着我国在晚期胃癌治疗模式上 向"居家化、门诊化"迈出关键一步，也为三生制药在肿瘤创新药赛道上打开了全新的增长空间。 图表一： 2025 国家医保目录（节选） | | 紫杉烷类 | | | | | --- | --- | --- | --- | --- | | | | 155 紫杉醇口服溶液 | 2027年12月31日 | 限一线含氟尿嘧啶类方案治疗期间或 治疗后出现疾病进展的晚期胃癌患者 | | XL01CD | | | | | 交银国际指出，更多新药进入目录有助于提升临床用药水平，及创新药行业整体研发回报率；商保资金的引入将为创 新药支付带来重要增量资金，为多元化支付体系的建立奠定基础。 中信建投指出，国家医保谈判成功率创历史新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此同时，中 国创新药管线国际化竞争力持续提升，出海模式 ...

港股方面，三大指数悉数下跌，百度集团、华虹半导体、哔哩哔哩跌幅居前。 | 恒生指数 | 恒生国企 | | 恒生科技 | | | --- | --- | --- | --- | --- | | 25684.64 | 9035.91 | | 5628.08 | | | -80.72 -0.31% | -47.62 -0.52% | | -34.47 -0.61% | | | 恒指期货 | 港股通50 | | 恒生生物科技 | | | 25727 | 3868.99 | | 0.00 | | | -50 -0.19% | -1.96 | -0.05% | 0.00 | 0.00% | 【导读】创新药概念股表现活跃，CPO板块走高 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 | 名称 | 现价 | 涨跌幅 = | 总市值 三 | | --- | --- | --- | --- | | 百度集团-SW | 122.000 ...